Connect your AI

CG Oncology CGON Change in Other Assets

Change in Other Assets at other companies

PfizerPFE

-$322.25M+61.9%

ImmunityBio, Inc.IBRX

$1.05M+1,152%

Cogent Biosciences, Inc.COGT

$1.84M+184%

Tango TherapeuticsTNGX

-$10K-900%

Immunovant, Inc.IMVT

-$1.3M-767%

Summit TherapeuticsSMMT

$1.03M-27.7%

Other financials

Income statement

Revenue$1.1M+1,983%

Operating income-$66.4M-57.3%

Net income-$60.2M-74.7%

EPS (diluted)-$0.71-57.8%

Balance sheet

Cash & equivalents$33.7M-18.7%

Total debt$7.6M+631%

Total equity$1.1B+54.9%

Total assets$1.1B+55.9%

Cash flow

Operating cash flow-$56.9M-94.5%

CapEx$304.0K+1,800%

Free cash flow-$57.2M-95.4%

Valuation

Market cap$5.39B+206%

Enterprise value$5.36B+212%

P/S1,062.4×-1,596×

Profitability

Operating margin-4,239%-1,872pp

Net margin-3,682.6%-1,601pp

FCF margin-3,163.8%-1,351pp

Returns & leverage

Return on equity-20.8%+7.1pp

Debt / equity0×0.0×

Current ratio31.3×+0.3×

Where this comes from

Reported directly by CG Oncology in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets.

The official record: CG Oncology’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about CG Oncology's change in other assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is CG Oncology's change in other assets?: CG Oncology (CGON) reported change in other assets of $8.07M in Q1 2026.
How has CG Oncology's change in other assets changed year-over-year?: CG Oncology's change in other assets increased by 1377.3% year-over-year, from $546K to $8.07M.
What does change in other assets mean?: Change in miscellaneous assets affecting operating cash flow.